Daniel H. Fowler, MD, discusses the challenges of graph-versus-host-disease (GVHD) in patients with high-risk lymphoma.
Daniel H. Fowler, MD, senior investigator, Center for Cancer Research, National Cancer Institute, discusses the challenges of graph-versus-host-disease (GVHD) in patients with high-risk lymphoma.
The most common problem when trying to cure lymphoma with a transplant is the lack of ability to control the disease, Fowler says. High-risk lymphoma types, such as diffuse large-cell lymphoma, transformed lymphoma, T cell lymphoma, and Hodgkin’s lymphoma, are more difficult to cure with a transplant when compared to other lymphoma types.
Fowler says another problem is that older patients do not handle the transplant well. Unfortunately, the median age of transplant patients with lymphoma is over 50 years old. Fowler says doctors have responded to this issue by reducing the amount of chemotherapy and radiation prior to the transplant, in order to get better results.
Another important aspect in the lymphoma transplant field is the patient’s disease state, Fowler says. Patients in complete remission or partial remission respond better than patients whose lymphoma is not responding to chemotherapy.
Fowler says half of his lymphoma patients are in the category of not responding to chemotherapy, but in clinical trials, these patients are seeing some favorable results.
Challenges for Non–CAR T-Cell Treatment of Early Relapsed DLBCL
April 18th 2024During a Case-Based Roundtable® event, Elizabeth A. Brém, MD, discussed treatment approaches for a patient with early relapsed or primary refractory diffuse large B-cell lymphoma in the first article of a 2-part series.
Read More
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Glofitamab Plus Chemo Improves Survival vs Rituximab in R/R DLBCL
April 16th 2024The phase 3 STARGLO trial met its primary end point, improving overall survival in patients with relapsed/refractory diffuse large B-cell lymphoma with glofitamab and chemotherapy vs rituximab and chemotherapy.
Read More